Compare Abeona Therapeutics Inc (ABEO) vs Kyndryl Holdings Inc (KD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Kyndryl Holdings Inc — how do they compare? Abeona Therapeutics Inc trades at $6.71 (market cap $373.32M), while Kyndryl Holdings Inc trades at $12.03 (market cap $2.73B). The key difference: Kyndryl Holdings Inc is far larger — about 7.3× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Kyndryl Holdings Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | KD | |
|---|---|---|
Market Cap | $373.32M | $2.73B |
Sector | Health | Technology |
52-Week High | $7.23 | $43.38 |
52-Week Low | $4.17 | $10.59 |
Enterprise Value | $228.22M | $5.07B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Kyndryl Holdings (KD) trades at $12.39, up 1.14% on the day, with a bullish technical signal from moving averages. The company reported revenue of $15.06B for 2025, achieving a net income of $252M, marking a return to profitability after losses in prior years. Recent news includes a partnership with Microsoft for sovereignty solutions and new executive appointments, but also legal investigations into the company's disclosures following a significant stock price decline earlier in 2026.
The outlook is mixed; improving cash flow and a low EV/EBITDA of 3.19 suggest undervaluation, but recent earnings misses and legal overhangs pose risks. Analyst consensus is a 'Hold' with a $14.33 price target, implying modest upside. Key investor focus is on the Q2 2026 earnings report due August 5, 2026, for confirmation of the profitability turnaround.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Kyndryl Holdings Inc
Kyndryl Holdings Inc is a technology services and infrastructure services provider company. It provides advisory, implementation, and managed services across a range of technology domains to help customers manage and modernize enterprise IT environments in support of their business and transformation objectives.
Read more on KD →
